AHC
REGN icon

Anderson Hoagland & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Anderson Hoagland & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-446
Closed -$344K – 142
2025
Q4 		$344K Hold
446
– – 0.03% 130
2025
Q3 		$251K Hold
446
– – 0.02% 135
2025
Q2 		$234K Sell
446
-89
-17% -$49.7K 0.02% 141
2025
Q1 		$298K Hold
535
– – 0.04% 127
2024
Q4 		$365K Sell
535
-2,854
-84% -$2.4M 0.04% 126
2024
Q3 		$3.43M Sell
3,389
-100
-3% -$111K 0.35% 79
2024
Q2 		$3.68M Hold
3,489
– – 0.39% 67
2024
Q1 		$3.27M Sell
3,489
-1,566
-31% -$1.49M 0.37% 77
2023
Q4 		$4.74M Sell
5,055
-55
-1% -$45.3K 0.58% 48
2023
Q3 		$4.21M Buy
5,110
+2
+0% +$1.57K 0.56% 42
2023
Q2 		$3.67M Hold
5,108
– – 0.47% 49
2023
Q1 		$4.2M Hold
5,108
– – 0.6% 44
2022
Q4 		$3.66M Buy
5,108
+588
+13% +$434K 0.53% 50
2022
Q3 		$3.11M Buy
4,520
+16
+0.4% +$10.1K 0.5% 54
2022
Q2 		$2.74M Hold
4,504
– – 0.41% 60
2022
Q1 		$3.15M Hold
4,504
– – 0.4% 60
2021
Q4 		$2.8M Buy
4,504
+89
+2% +$54.7K 0.37% 70
2021
Q3 		$2.67M Buy
+4,415
New +$2.74M 0.34% 70
2021
Q1 		– Sell
-2,624
Closed -$1.27M – 112
2020
Q4 		$1.27M Buy
2,624
+1,074
+69% +$580K 0.2% 85
2020
Q3 		$967K Sell
1,550
-50
-3% -$30.3K 0.46% 57
2020
Q2 		$998K Buy
+1,600
New +$908K 0.47% 58
2017
Q1 		– Sell
-1,400
Closed -$514K – 109
2016
Q4 		$514K Hold
1,400
– – 0.3% 88
2016
Q3 		$563K Hold
1,400
– – 0.32% 85
2016
Q2 		$489K Hold
1,400
– – 0.3% 82
2016
Q1 		$505K Buy
+1,400
New +$577K 0.31% 73

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Anderson Hoagland & Co's REGN Position: Q1 2026 in Review

Anderson Hoagland & Co sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 446 shares — an estimated $344K sold.

Anderson Hoagland & Co first reported a position in REGN in Q1 2016 and held it in 25 quarters. The position peaked at $4.74M in Q4 2023. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Anderson Hoagland & Co reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Anderson Hoagland & Co sold 446 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $344K.
  • Anderson Hoagland & Co first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 25 quarters.
  • Anderson Hoagland & Co's Regeneron Pharmaceuticals position peaked at $4.74M in Q4 2023.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Anderson Hoagland & Co's 13F filing for Q1 2026, filed 7 Apr 2026.